Comparison of Dabigatran vs. Warfarin in Acute Vnous Thromboemboly: Systematic Review
Authors
Abstract:
abstract:Acute Venous Thromboembolism (VTE) is a common disease associated with the significant morbidity and mortality. We reviewed clinical outcomes systematically with Dabigatran as a direct oral anticoagulants (DOAC) for treatment of acute VTE. We used Ovide, PubMed, Cochrane (CENTRAL), EMBASE, Scopus, Science Direct, LILAC(for article written not English) and also Iranian database; Magiran, Isc, Iran Medex, Iran DOC, Doaj up to May 2014 to identify randomized clinical trials of Dabigatran compared with conventional treatment for VTE. Two investigators extracted data independently. Number of 5107 patients including two trails were selected. The risk of recurrent VTE was similar with the Dabigatran and standard treatment (Hazard Ratio, 95% confidence interval 1.09 (0.76–1.57). Dabigatran reduced the risk of minor bleeding in comparison with standard treatment; Warfarin (0.62 (0.50–0.76). Finally- in minor bleeding - the Dabigatran seemed as effective as, and probably safer than standard treatment of acute VTE. But in some aspects such as adherence to treatment, pregnant patient, impact on quality of life, new researches are needed to be clarified.
similar resources
comparison of dabigatran vs. warfarin in acute vnous thromboemboly: systematic review
abstract:acute venous thromboembolism (vte) is a common disease associated with the significant morbidity and mortality. we reviewed clinical outcomes systematically with dabigatran as a direct oral anticoagulants (doac) for treatment of acute vte. we used ovide, pubmed, cochrane (central), embase, scopus, science direct, lilac(for article written not english) and also iranian database; magiran...
full textDabigatran versus Warfarin in the Treatment of Acute Venous Thromboembolism
From the Department of Medicine, McMaster University and Henderson Research Centre, Hamilton, ON, Canada (S. Schulman, C.K.); the Department of Hematology, Karolinska University Hospital, Stockholm (S. Schulman); Thrombosis Research Institute and Queen Mary University of London, London (A.K.K.); the Department of Vascular Pathology, Bellevue Hospital, Saint Etienne, France (P.M.); Medical Divis...
full textAcute myocardial infarction after switching from warfarin to dabigatran.
Dabigatran etexilate is a recently approved direct thrombin inhibitor (DTI), which is superior to warfarin in the prevention of stroke and systemic embolism in patients with atrial fibrillation (AF). However, dabigatran use is associated with an increased risk of myocardial infarction (MI) compared to warfarin. The mechanisms for this association effect remain speculative. We present a case of ...
full textMy Resources
Journal title
volume 15 issue 2
pages 611- 617
publication date 2016-06-01
By following a journal you will be notified via email when a new issue of this journal is published.
Hosted on Doprax cloud platform doprax.com
copyright © 2015-2023